CELDA to Copenhagen

Likvor Ltd, a medical device company in Umeå, has further strengthened its presence outside of Sweden by selling Likvor CELDA® System to Rigshospitalet in Copenhagen. The system is used to better diagnose patients with treatable dementia, NPH, and has attracted much attention.

Likvor AB already has a system in Denmark, at the University Hospital in Aalborg, and in December 2012 the company received an additional customer in Denmark by the order from the neurological department at Rigshospitalet in Copenhagen. By this order Likvor reinforces its presence outside Sweden and has 10 systems outplaced at different clinics. In Europe, there are customers in Finland, Denmark, England and the Netherlands, and we expect to outplace additional number of systems in 2013, says CEO Maria Wallin Wållberg.

One in ten dementia patients are estimated, in fact, to be suffering from treatable dementia, NPH, a hidden and often difficult diagnosed disease. Symptoms of NPH include gait disturbance, mild dementia and incontinence. Those affected are often over 55 years. Unlike dementia, NPH can be treated with a relatively simple operation, insertion of a shunt.

Likvor CELDA® System is the most advanced instrument for accurately characterize the dynamic and flow of cerebrospinal fluid (CSF) that surrounds the brain and spinal cord before and after insertion of a shunt. By using Likvor CELDA® System to determine shunt functionality, unnecessary shunt operations can be avoided saving society money and the individual patient suffering.


For more information on Likvor and Likvor CELDA® System, visit www.likvor.com or contact CEO, Maria Wallin Wållberg: +46 (0) 70 588 6766, maria.wallinwallberg @ likvor.com

Likvor AB develops and sells products to accurately characterize the dynamics of the CSF-fluid system, that surrounds the brain and spinal cord. The business is based on world-leading research in NPH at Norrland’s University Hospital in Umeå, Umeå University.

Owners of Likvor AB is Uminova Invest, Partner Invest North, Stimor Invest and Kjell Öberg.